drugset
drugset / Trial / NCT05914376

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

NCT05914376 ↗

Phase 1 Active not recruiting 24 enrolled Hangzhou Converd Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.

Timeline

Start
2023-07-05
Primary completion
2025-07-02
Completion
2027-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject hV01 Unknown 1e+07 unknown Other
Subject hV01 Unknown 8e+08 unknown Other

Indications

cancer